JP Morgan Chase’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21 Hold
13
﹤0.01% 7406
2025
Q4
$26 Sell
13
-565,426
-100% -$1.81M ﹤0.01% 7286
2025
Q3
$1.65M Sell
565,439
-191,622
-25% -$441K ﹤0.01% 4223
2025
Q2
$1.37M Sell
757,061
-32,955
-4% -$58.6K ﹤0.01% 4190
2025
Q1
$1.19M Buy
790,016
+388,681
+97% +$981K ﹤0.01% 4235
2024
Q4
$947K Buy
401,335
+364,982
+1,004% +$6.41M ﹤0.01% 4669
2024
Q3
$1.07M Sell
36,353
-19,524
-35% -$450K ﹤0.01% 4425
2024
Q2
$690K Buy
55,877
+3
+0% +$63 ﹤0.01% 4503
2024
Q1
$1.13M Buy
55,874
+745
+1% +$17.2K ﹤0.01% 4253
2023
Q4
$1.24M Buy
55,129
+5,926
+12% +$125K ﹤0.01% 4190
2023
Q3
$819K Sell
49,203
-6,417
-12% -$127K ﹤0.01% 4190
2023
Q2
$1.36M Buy
55,620
+6,013
+12% +$145K ﹤0.01% 3819
2023
Q1
$1.2M Buy
49,607
+10,242
+26% +$284K ﹤0.01% 3916
2022
Q4
$1.16M Buy
39,365
+4,239
+12% +$152K ﹤0.01% 3939
2022
Q3
$1.47M Sell
35,126
-20,740
-37% -$560K ﹤0.01% 3723
2022
Q2
$1.57M Buy
55,866
+27,148
+95% +$686K ﹤0.01% 3735
2022
Q1
$1.07M Buy
28,718
+4,123
+17% +$175K ﹤0.01% 4219
2021
Q4
$1.07M Buy
24,595
+1,546
+7% +$81.1K ﹤0.01% 4339
2021
Q3
$1.43M Sell
23,049
-2,808
-11% -$234K ﹤0.01% 4043
2021
Q2
$2.21M Sell
25,857
-22,776
-47% -$1.22M ﹤0.01% 3726
2021
Q1
$2.19M Buy
48,633
+34,122
+235% +$1.34M ﹤0.01% 3656
2020
Q4
$99K Buy
14,511
+5,871
+68% +$52.4K ﹤0.01% 4998
2020
Q3
$99K Buy
8,640
+845
+11% +$3.81K ﹤0.01% 4697
2020
Q2
$24K Buy
+7,795
New +$35.4K ﹤0.01% 5004
2019
Q3
Sell
-13,743
Closed -$17K 5924
2019
Q2
$17K Buy
+13,743
New +$15.6K ﹤0.01% 5476
2014
Q4
Sell
-3,404
Closed -$93K 4340
2014
Q3
$93K Sell
3,404
-628
-16% -$19.1K ﹤0.01% 4092
2014
Q2
$163K Sell
4,032
-2,170
-35% -$80.3K ﹤0.01% 3404
2014
Q1
$239K Buy
6,202
+2,798
+82% +$98.8K ﹤0.01% 3365
2013
Q4
$116K Sell
3,404
-18
-0.5% -$478 ﹤0.01% 3884
2013
Q3
$65K Sell
3,422
-170
-5% -$2.97K ﹤0.01% 4233
2013
Q2
$56K Buy
+3,592
New +$75.9K ﹤0.01% 4258

Other funds holding FLNA

JP Morgan Chase's FLNA Position: Q1 2026 in Review

JP Morgan Chase held its Filana Therapeutics (FLNA) position steady in Q1 2026 at 13 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #7406.

JP Morgan Chase first reported a position in FLNA in Q2 2013 and has held it in 31 quarters since. The position peaked at $2.21M in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • JP Morgan Chase held 13 shares of Filana Therapeutics worth $21 as of Q1 2026.
  • JP Morgan Chase left its Filana Therapeutics share count unchanged in Q1 2026.
  • Filana Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7406 holding.
  • JP Morgan Chase first reported a position in Filana Therapeutics in Q2 2013 and has held it in 31 quarters since.
  • JP Morgan Chase's Filana Therapeutics position peaked at $2.21M in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.